Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification

Toxicological Sciences

Volumn 115, Issue 1, 2010, Pages 66-79

  Jennen, Danyel G J ^a,b   Magkoufopoulou, Christina ^a,b   Ketelslegers, Hans B ^a,c   van Herwijnen, Marcel H M ^a   Kleinjans, Jos C S ^a,b   van Delft, Joost H M ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Netherlands Toxicogenomics Centre   (Netherlands)

^c EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

Author keywords

Carcinogens; Class discrimination; Comparison; HepaRG; HepG2; Microarray

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AFLATOXIN B1; BENZO[A]PYRENE; CYCLOSPORIN A; ESTRADIOL; CARCINOGEN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL STRAIN; CELL STRAIN HEPARG; CELL STRAIN HEPG2; CHEMICAL ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOTOXICITY; HAZARD ASSESSMENT; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LIVER; LIVER CELL; METABOLISM; TRANSCRIPTION REGULATION; ANIMAL TESTING ALTERNATIVE; CARCINOGEN TESTING; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOMICS; METHODOLOGY; PREDICTION AND FORECASTING; RISK ASSESSMENT;

ANIMAL USE ALTERNATIVES; CARCINOGENICITY TESTS; CARCINOGENS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HEP G2 CELLS; HEPATOCYTES; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 79551687759     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq026     Document Type: Article

References (42)

1. Backman, L., Appelkvist, E. L., Sundberg, A., Teclebrhan, H., and Brunk, U. (1991). Modulation of metabolism in HepG2 cells upon treatment with cyclosporin A and Nva2-cyclosporin. Exp. Mol. Pathol. 54, 242-254.
2. Burczynski, M. E., McMillian, M., Ciervo, J., Li, L., Parker, J. B., Dunn, R. T., II., Hicken, S., Farr, S., and Johnson, M. D. (2000). Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol. Sci. 58, 399-415.
3. Dai, M., Wang, P., Boyd, A. D., Kostov, G., Athey, B., Jones, E. G., Bunney, W. E., Myers, R. M., Speed, T. P., Akil, H., et al. (2005). Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175.
4. Davila, J. C., Rodriguez, R. J., Melchert, R. B., and Acosta, D., Jr. (1998). Predictive value of in vitro model systems in toxicology. Annu. Rev. Pharmacol. Toxicol. 38, 63-96.
5. De Groot, P. J., Reiff, C., Mayer, C., and Muller, M. (2008). NuGO contributions to GenePattern. Genes Nutr. 3, 143-146.
6. Endo, K., Uno, S., Seki, T., Ariga, T., Kusumi, Y., Mitsumata, M., Yamada, S., and Makishima, M. (2008). Inhibition of aryl hydrocarbon receptor transactivation and DNA adduct formation by CYP1 isoform-selective metabolic deactivation of benzo[a]pyrene. Toxicol. Appl. Pharmacol. 230, 135-143.
7. Gelboin, H. V. (1980). Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol. Rev. 60, 1107-1166.
8. Gueguen, Y., Ferrari, L., Souidi, M., Batt, A. M., Lutton, C., Siest, G., and Visvikis, S. (2007). Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin. Pharmacol. Toxicol. 100, 392-397.
9. Guengerich, F. P. (2008). Cytochrome p450 and chemical toxicology. Chem. Res. Toxicol. 21, 70-83.
10. Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., and Guguen-Guillouzo, C. (2007). The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168, 66-73.
11. Harries, H. M., Fletcher, S. T., Duggan, C. M., and Baker, V. A. (2001). The use of genomics technology to investigate gene expression changes in cultured human liver cells. Toxicol. In Vitro 15, 399-405.
12. Harris, A. J., Dial, S. L., and Casciano, D. A. (2004). Comparison of basal gene expression profiles and effects of hepatocarcinogens on gene expression in cultured primary human hepatocytes and HepG2 cells. Mutat. Res. 549, 79-99.
13. Hockley, S. L., Arlt, V. M., Brewer, D., Giddings, I., and Phillips, D. H. (2006). Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2. BMC Genomics 7, 260.
14. Hong, Y., Muller, U. R., and Lai, F. (2003). Discriminating two classes of toxicants through expression analysis of HepG2 cells with DNA arrays. Toxicol. In Vitro 17, 85-92.
15. Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsh, J. A., Sun, T., and Harris, C. C. (1993). p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14, 987-992.
16. Irizarry, R. A., Hobbs, B., Collin, F., Beazer-Barclay, Y. D., Antonellis, K. J., Scherf, U., and Speed, T. P. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
17. Jiang, H., Gelhaus, S. L., Mangal, D., Harvey, R. G., Blair, I. A., and Penning, T. M. (2007). Metabolism of benzo[a]pyrene in human bronchoalveolar H358 cells using liquid chromatography-mass spectrometry. Chem. Res. Toxicol. 20, 1331-1341.
18. Kamdem, L. K., Meineke, I., Godtel-Armbrust, U., Brockmoller, J., and Wojnowski, L. (2006). Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem. Res. Toxicol. 19, 577-586.
19. Kanebratt, K. P., and Andersson, T. B. (2008a). Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36, 1444-1452.
20. Kanebratt, K. P., and Andersson, T. B. (2008b). HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab. Dispos. 36, 137-145.
21. Knasmuller, S., Parzefall, W., Sanyal, R., Ecker, S., Schwab, C., Uhl, M., Mersch-Sundermann, V., Williamson, G., Hietsch, G., Langer, T., et al. (1998). Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat. Res. 402, 185-202.
22. Lambert, C. B., Spire, C., Claude, N., and Guillouzo, A. (2009). Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol. Appl. Pharmacol. 234, 345-360.
23. Levy, J., Budai, K., and Javitt, N. B. (1994). Bile acid synthesis in HepG2 cells: effect of cyclosporin. J. Lipid Res. 35, 1795-1800.
24. Liguori, M. J., Blomme, E. A., and Waring, J. F. (2008). Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab. Dispos. 36, 223-233.
25. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
26. Murray, G. I., Melvin, W. T., Greenlee, W. F., and Burke, M. D. (2001). Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. 41, 297-316.
27. New, D. C., and Wong, Y. H. (2007). Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J.Mol. Signal. 2,2.
28. NTP. (2005). NTP 11th Report on Carcinogens. Rep. Carcinog. 11, 1-A32.
29. Olsavsky, K. M., Page, J. L., Johnson, M. C., Zarbl, H., Strom, S. C., and Omiecinski, C. J. (2007). Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol. Appl. Pharmacol. 222, 42-56.
30. Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., and Mesirov, J. P. (2006). GenePattern 2.0. Nat. Genet. 38, 500-501.
31. Shaw, P. M., Barnes, T. S., Cameron, D., Engeset, J., Melvin, W. T., Omar, G., Petrie, J. C., Rush, W. R., Snyder, C. P., Whiting, P. H., et al. (1989). Purification and characterization of an anticonvulsant-induced human cytochrome P-450 catalysing cyclosporin metabolism. Biochem. J. 263, 653-663.
32. Tibshirani, R., Hastie, T., Narasimhan, B., and Chu, G. (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. U.S.A. 99, 6567-6572.
33. Tong, W., Cao, X., Harris, S., Sun, H., Fang, H., Fuscoe, J., Harris, A., Hong, H., Xie, Q., Perkins, R., et al. (2003). ArrayTrack-supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ. Health Perspect. 111, 1819-1826.
34. Tong, W., Harris, S., Cao, X., Fang, H., Shi, L., Sun, H., Fuscoe, J., Harris, A., Hong, H., Xie, Q., et al. (2004). Development of public toxicogenomics software for microarray data management and analysis. Mutat. Res. 549, 241-253.
35. Tsuchiya, Y., Nakajima, M., and Yokoi, T. (2005). Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 227, 115-124.
36. Turpeinen, M., Tolonen, A., Chesne, C., Guillouzo, A., Uusitalo, J., and Pelkonen, O. (2009). Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol. In Vitro 23, 748-753.
37. van Delft, J. H., van Agen, E., van Breda, S. G., Herwijnen, M. H., Staal, Y. C., and Kleinjans, J. C. (2004). Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 25, 1265-1276.
38. van Delft, J. H., van Agen, E., van Breda, S. G., Herwijnen, M. H., Staal, Y. C., and Kleinjans, J. C. (2005). Comparison of supervised clustering methods to discriminate genotoxic from non-genotoxic carcinogens by gene expression profiling. Mutat. Res. 575, 17-33.
39. Watkins, P. B. (1990). The role of cytochromes P-450 in cyclosporine metabolism. J. Am. Acad. Dermatol. 23, 1301-1309; discussion 1309-1311.
40. Westerink, W. M., and Schoonen, W. G. (2007a). Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21, 1581-1591.
41. Westerink, W. M., and Schoonen, W. G. (2007b). Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro 21, 1592-1602.
42. Wilkening, S., Stahl, F., and Bader, A. (2003). Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos. 31, 1035-1042.